# Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

> **NCT03430791** · PHASE2 · TERMINATED · sponsor: **Baptist Health South Florida** · enrollment: 5 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Nivolumab 240 mg IV
- **DRUG:** Nivolumab 3 mg/kg
- **DRUG:** Ipilimumab 1 mg/kg
- **DEVICE:** NovoTTF200A (Optune)

## Key facts

- **NCT ID:** NCT03430791
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-05
- **Primary completion:** 2020-05-29
- **Final completion:** 2021-01-27
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study Investigator/Sponsor decided to end enrollment earlier.
- **Last updated:** 2023-02-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430791, "Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03430791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*